Mitochondria are essential for energy production, metabolic signaling, calcium homeostasis, and other roles. Consequently, mitochondrial dysfunction is associated with several human pathologies including neurodegenerative, cardiovascular, and metabolic diseases, as well as cancer. Thus, cells use recovery mechanisms such as the mitochondrial unfolded protein response (UPRmt) to mediate mitochondrial recovery. Importantly, the UPRmt may have clinical relevance as it has been shown to play a role in cancer survival. Hence, inhibition of the UPRmt may be leveraged as an anticancer strategy with great therapeutic promise. We employed a whole-animal chemical screening approach to identify small molecule inhibitors of the UPRmt using the C. elegans UPRmt transcriptional GFP reporter strain
hsp-6::GFP. We screened a library of 1280 FDA-approved drugs for their ability to inhibit
hsp-6::GFP reporter expression during stress. Among the identified hits was Paroxetine (Paxil), a type of selective serotonin reuptake inhibitor (SSRI) that blocks serotonin transporters on the presynaptic membrane, thereby increasing the concentration of this neurotransmitter at the synapse. Serotonin stabilizes our mood and feelings of well-being. Thus, SSRIs are used in the treatment of depression and other mental disorders. The connection between the SSRI Paroxetine and the activity of the UPRmt, however, has not been previously reported. Consistent with suppression of the UPRmt, Paroxetine further impaired mitochondrial function during stress but had negligible effects under standard conditions. Importantly, Paroxetine did not suppress other cellular stress response pathways including the endoplasmic reticulum UPR (UPRER). In addition, Paroxetine suppressed UPRmt-associated phenotypes including extensions in lifespan and increased host survival during infection. Unexpectedly, genetically disabling the clinical target of Paroxetine, the serotonin reuptake transporter
mod-5, did not suppress UPRmt. Therefore, Paroxetine likely disables UPRmt activity through an unconventional drug target.